Page 15 - Biological E News Today

Last Updated: Johnson & Johnsons One-shot Janssen COVID-19 Vaccine: Here Is All You Need To Know Johnson & Johnson has announced that it is collaborating with Telangana-based Biological E to produce its Janssen COVID-19 vaccine in India. Image- AP Pharma giant Johnson & Johnson on Tuesday announced that it is manufacturing its COVID-19 vaccine-- Janssen/ J&J vaccine in collaboration with Telangana-based Biological E. Limited in India. Johnson & Johnsons single-dose vaccine would add a sig...

Biological E. to produce J&J Covid-19 vaccine Reuters New Delhi | Updated on May 19, 2021 Move will boost India’s overall supplies amid a shortage Biological E. will produce the Johnson & Johnson Covid-19 vaccine alongside its own candidate, its managing director told Reuters on Tuesday, which could boost the India’s overall supplies amid a shortage. “The infrastructure and plants are completely separate for both the products and we will be producing both independent of each other,” Mah...

Johnson and Johnson to manufacture COVID-19 vaccine with Telangana-based Biological E Johnson & Johnson US pharmaceutical giant Johnson and Johnson has joined hands with Biological E Limited (Telangana-based pharma company) for the manufacturing of the COVID-19 vaccine, as per an official statement on Tuesday. The companys vaccine named, Janssen COVID-19 vaccine is currently approved for use in the United States, the European Union and other nations including Thailand and South Africa. "Johnso...

Apart from Serum, Bharat Biotech, these 5 vaccine makers are Indias hope against Covid-19 The current vaccine makers, Serum Institute and Bharat Biotech, alone wont be able to meet the demand. There are other players too in vaccine production, and they should be able to cater to the demand in the months ahead Manoj Sharma | May 17, 2021 | Updated 11:19 IST The government has said India will produce a total of 126 crore vaccines between August-December A crucial part of Indias fight against sec...

The Centre has claimed that India will have access to over 2 billion doses of eight Covid-19 vaccines between August and December, making them available for everyone. Out of these eight, two – Covishield and Covaxin – are already in circulation. But what do we know about the other six? Let’s find out…

Read more about Biological E to start phase 3 clinical trials of its Covid-19 vaccine soon on Business Standard. The phase III clinical study, to be conducted in 15 sites across India, will evaluate the immunogenicity and safety of Biological Es vaccine candidate in 1,268 healthy subjects

April 24, 2021 The Phase III clinical study to be conducted in 15 sites across India Biological E. Ltd, has successfully completed the Phase I and II clinical trial of its Covid-19 subunit vaccine candidate in India and received the approval to start the Phase III clinical trial from the Central Drugs Standard Control Organization (CDSCO) - Subject Expert Committee (SEC). Its candidate includes an antigen developed by Texas Children’s Hospital Center for Vaccine Development and in-licensed ...

Biological E to initiate Ph III trial of COVID-19 vaccine candidate Biological E to initiate Ph III trial of COVID-19 vaccine candidate 24 April 2021 | News Image credit- shutterstock.com Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company, has announced that it has successfully completed the Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India and received the approval to start the Phase III clinical trial from the Central Drugs Standard C...

J&Js Single-Dose Covid-19 Vaccine Likely To Be Imported To India By June-July: DBT Secretary Renu Swarup (A picture of vaccine vials from Johnson and Johnson) United States (US) based pharmaceutical major Johnson & Johnson (J&J) is working closely with Hyderabad based vaccine maker Biological E to facilitate the technology transfer for domestic manufacturing of its single-dose COVID-19 vaccine in India while it is expected that the vaccines import into the country will begin by June-July, repor...

Department of Biotechnology Secretary Renu Swarup. File   Renu Swarup said a financial support of ₹400 crore is being provided to vaccine candidates from Zydus Cadilla, Biological E, Gennova and Bharat Biotech Efforts are being ramped up for massive production of vaccines and make them available in the shortest possible time, a top government official said on Wednesday, stressing that India currently has a promising pipeline of four-five COVID-19 vaccine candidates, while three have alrea...